Gubra’s Innovation in Peptide-Based Drug Discovery

Published

About this Series

Architects of Innovation

Nasdaq’s Architects of Innovation series seeks to uncover stories of innovation and technology across the global financial system. In these episodes we dive into Nasdaq’s leadership in the European capital markets and how our innovative approach has helped foster a thriving financial ecosystem.

Founded in 2008, Gubra is a highly specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. In this interview, CEO Henrik Blou reflects on Gubra’s path to becoming a public company — from the strategic decision to list, to the importance of simplifying a complex business model, and how public capital is fueling their next phase of growth.

More in this Series

See all

Nasdaq Watch

See what's playing at Nasdaq

Watch Now